Concepedia

Matthew Holderfield

MH

Statistics

Publications

20

Citations

2.5K

H-Index

19

Active since

2005

Affiliations

Revolution Medicines (United States)(Current)

Harvard University

Leidos (United States)

Broad Institute

Frederick National Laboratory for Cancer Research

Matthew Holderfield is an author at Revolution Medicines (United States) specializing in oncology, molecular oncology, and life sciences.

ORCID

Publications per year

2005–2025

20

Publications

20

TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype

Richard C.A. Sainson, Douglas A. Johnston, Henry C. Chu et al. · Blood · 2008 · 323 citations · Full text

, , +16

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Matthew Holderfield, Bianca J. Lee, Jingjing Jiang et al. · Nature · 2024 · 318 citations · Full text

, , +16

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato et al. · Cancer Discovery · 2024 · 281 citations · Full text

, , +17

Cell‐autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis

Richard C.A. Sainson, Jason Aoto, Martin N. Nakatsu et al. · The FASEB Journal · 2005 · 227 citations

, , +15

K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling

Man-Tzu Wang, Matthew Holderfield, Jacqueline Galeas et al. · Cell · 2015 · 195 citations · Full text

, , +14

1–5 of 20